Effects of ethnicity on overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) being treated with Sorafenib

Trial Profile

Effects of ethnicity on overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) being treated with Sorafenib

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Feb 2018 New trial record
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top